Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma. Issue 1 (21st September 2021)

• Record Type: Journal Article
• Authors: Varlet, Pascale; Bouffet, Eric; Casanova, Michela; Giangaspero, Felice; Antonelli, Manila; Hargrave, Darren; Ladenstein, Ruth; Pearson, Andy; Hawkins, Cynthia; König, Fatima Barbara; Rüschoff, Josef; Schmauch, Christian; Bühnemann, Claudia; Garin‐Chesa, Pilar; Schweifer, Norbert; Uttenreuther‐Fischer, Martina; Gibson, Neil; Ittrich, Carina; Krämer, Nicole; Solca, Flavio; Stolze, Britta; Geoerger, Birgit
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-09-21
• Subjects: biomarkers -- CNS cancers -- drug targets -- molecular oncology -- pediatric cancers -- protein tyrosine kinases; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29316
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: There is a paucity of knowledge regarding pediatric biomarkers, including the relevance of ErbB pathway aberrations in pediatric tumors. We investigated the occurrence of ErbB receptor aberrations across different pediatric malignancies, to identify patterns of ErbB dysregulation and define biomarkers suitable for patient enrichment in clinical studies. Procedure: Tissue samples from 297 patients with nervous system tumors and rhabdomyosarcoma were analyzed for immunohistochemical expression or gene amplification of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). Exploratory analyses of HER3/HER4 expression, and mRNA expression of ErbB receptors/ligands (NanoString) were performed. Assay validation followed general procedures, with additional validation to address Clinical Laboratory Improvement Amendments (CLIA) requirements. Results: In most tumor types, samples with high ErbB receptor expression were found with heterogeneous distribution. We considered increased/aberrant ErbB pathway activation when greater than or equal to two EGFR/HER2 markers were simultaneously upregulated. ErbB pathway dysregulation was identified in ∼20%–30% of samples for most tumor types (medulloblastoma/primitive neuroectodermal tumors 31.1%, high‐grade glioma 27.1%, neuroblastoma 22.7%, rhabdomyosarcoma 23.1%, ependymoma 18.8%), 4.2% of diffuse intrinsic pontine gliomas, and no recurrent or refractory low‐grade astrocytomas. In medulloblastoma/primitive neuroectodermal tumors and neuroblastoma, this was attributed mainly to high EGFR polysomy/HER2 amplification, whereas EGFR gene amplification was observed in some high‐grade glioma samples. EGFR/HER2 overexpression was most prevalent in ependymoma. Conclusions: Overexpression and/or amplification of EGFR/HER2 were identified as potential enrichment biomarkers for clinical trials of ErbB‐targeted drugs.